Cue Biopharma (CUE) Retained Earnings (2017 - 2025)
Cue Biopharma (CUE) posted Retained Earnings of -$368.5 million for Q4 2025, little changed sequentially from -$370.1 million in Q3 2025, and down 7.78% YoY from -$399.6 million in Q4 2024.
Cue Biopharma (CUE) Retained Earnings (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Retained Earnings for 9 years, with the latest figure at -$368.5 million in Q4 2025.
- Quarterly Retained Earnings fell 7.78% year-over-year to -$368.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$368.5 million (down 7.78% YoY) and the FY2025 annual result came in at -$368.5 million, down 7.78% from the prior year.
- Retained Earnings was little changed at -$368.5 million in Q4 2025 per CUE's latest filing, from -$370.1 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$92000.0 in Q3 2022 and troughed at -$370.1 million in Q3 2025.
- A 5-year average of -$265.6 million and a median of -$282.3 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2021 and 2022: Retained Earnings tumbled 2768943.28% in 2021, then surged 99.95% in 2022.
- Over 5 years, Retained Earnings stood at -$197.4 million in 2021, then declined by 26.85% to -$250.5 million in 2022, then dropped by 20.26% to -$301.2 million in 2023, then decreased by 13.5% to -$341.9 million in 2024, then retreated by 7.78% to -$368.5 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$368.5 million, -$370.1 million, and -$362.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | -526.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -368.47 Mn |
| Sep 30, 2025 | -370.05 Mn |
| Jun 30, 2025 | -362.60 Mn |
| Mar 31, 2025 | -354.12 Mn |
| Dec 31, 2024 | -341.86 Mn |
| Sep 30, 2024 | -332.37 Mn |
| Jun 30, 2024 | -323.71 Mn |
| Mar 31, 2024 | -313.54 Mn |
| Dec 31, 2023 | -301.19 Mn |
| Sep 30, 2023 | -287.76 Mn |
| Jun 30, 2023 | -276.75 Mn |
| Mar 31, 2023 | -263.57 Mn |
| Dec 31, 2022 | -250.46 Mn |
| Sep 30, 2022 | -92,000.00 |
| Jun 30, 2022 | -224.91 Mn |
| Mar 31, 2022 | -211.70 Mn |
| Dec 31, 2021 | -197.45 Mn |
| Sep 30, 2021 | -189.06 Mn |
| Jun 30, 2021 | -176.07 Mn |
| Mar 31, 2021 | -165.79 Mn |